142072-07-9

Usage

Uses

Used in Pharmaceutical Industry:
1-Propanol, 2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]is used as an intermediate in the synthesis of Cetirizine (C291155), a non-sedating type histamine H1-receptor antagonist. This application is significant because Cetirizine is widely used to treat various allergic conditions, such as rhinitis, urticaria, and atopic dermatitis, by blocking the action of histamine, a substance released by the body during an allergic response.
In the synthesis of Cetirizine, 1-Propanol, 2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]serves as a key building block that contributes to the formation of the final drug molecule. Its unique silyl ether functional group allows for selective reactions and modifications, enabling the development of Cetirizine with improved pharmacological properties and reduced side effects.
Furthermore, the use of 1-Propanol, 2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]in the pharmaceutical industry highlights its potential in the development of other drug molecules with diverse therapeutic applications. Its ability to form stable covalent bonds and its compatibility with various synthetic strategies make it a valuable compound for the design and synthesis of novel pharmaceutical agents.

Upstream product

• 57-55-6 propylene glycol 
• 29681-57-0 tert-butyldimethylsilane 
• 119404-55-6 2-(tert-butyl-dimethyl-silanyloxy)-propionic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1009334-99-9 (2-benzyloxy-1-methyl-ethoxy)-tert-butyl-dimethyl-silane 
• 105198-38-7 (S)-(-)-ethyl 2-(tert-butyldimethylsilyloxy)propanoate 
• 142072-00-2 2-(tert-Butyl-dimethyl-silanyloxy)-1-triethylsilanyloxy-propane 

Relevant academic research and scientific papers

Evidence That Nucleophile Deprotonation Exceeds Bond Formation in the HDV Ribozyme Transition State

Steric constraints imposed by the active sites of protein and RNA enzymes pose major challenges to the investigation of structure-function relationships within these systems. As a strategy to circumvent such constraints in the HDV ribozyme, we have synthesized phosphoramidites from propanediol derivatives and incorporated them at the 5′-termini of RNA and DNA oligonucleotides to generate a series of novel substrates with nucleophiles perturbed electronically through geminal fluorination. In nonenzymatic, hydroxide-catalyzed intramolecular transphosphorylation of the DNA substrates, pH-rate profiles revealed that fluorine substitution reduces the maximal rate and the kinetic pKa, consistent with the expected electron-withdrawing effect. In HDV ribozyme reactions, we observed that the RNA substrates undergo transphosphorylation relatively efficiently, suggesting that the conformational constraints imposed by a ribofuranose ring are not strictly required for ribozyme catalysis. In contrast to the nonenzymatic reactions, however, substrate fluorination modestly increases the ribozyme reaction rate, consistent with a mechanism in which (1) the 2′-hydroxyl nucleophile exists predominantly in its neutral, protonated form in the ground state and (2) the 2′-hydroxyl bears some negative charge in the rate-determining step, consistent with a transition state in which the extent of 2′-OH deprotonation exceeds the extent of P-O bond formation.

Method for producing alcohols

A method for producing alcohols which comprises reducing esters or lactones with hydrogen gas in the presence of a catalyst comprising (i) a ruthenium compound, (ii) a monodentate monophosphine or a bidentate bisphosphine, and (iii) an amine. Examples of the catalyst include a ruthenium (Ru) complex represented by the formula:RuX1X2(LP)m(LN)n [X1 and X2 each represent an anionic ligand, LP represents a phosphine ligand, m is 1 when LP is bidentate, while m is 2 when LP is monodentate, LN represents an amine ligand, and n is 1 when LN is bidentate, while n is 2 when LN is monodentate.] and a catalyst comprising an amine and a ruthenium (Ru) complex of the formula: RuX1X2 (LP1)r [LP1 represents a monophosphine ligand and r is 3 or 4.].

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Stereoselective Radical Additions of γ-Oxy-α,β-unsaturated Ester Derivatives; 1,2-Asymmetric Induction in Acyclic and Cyclisation Systems

Examination was made of 1,2-asymmetric induction in the addition of alkyl radicals to γ-oxy-α,β-unsaturated ester derivatives 1 and 2 prepared from ethyl lactate and (R)-2,3-O-isopropylideneglyceraldehyde 3, respectively.The addition reactions of hexyl, cyclohexyl and 3-phenylpropyl radicals to (Z)-2 derived from aldehyde 3 gave β-addition products with syn-stereoselectivity (syn:anti = 8.6:1 - syn only).The reactions of (E)-2 were non-stereoselective.Based on allylic strain, a transition-state model for the syn-stereoselectivity is proposed. 1,2-Asymmetric induction was carried out in radical cyclisation to synthesize optically active cyclohexane derivatives.

A Novel Deacylation Method using Grignard Reagent without affecting the Neighbouring Base-sensitive Functional Groups

Methyl and ethyl Grignard reagents are shown to cleave ester functions such as benzoate and acetate without affecting the neighbouring base-sensitive functional groups.

The Utility of t-Butyldimethylsilane as an Effective Silylation Reagent for the Protection of Functional Groups

Treatment of compounds containing functional groups, such as alcohols, amines, and carboxylic acids, with t-butyldimethylsilane in the presence of a catalytic amount of palladium on carbon is described to provide a new, convenient method for the introduction of a t-butyldimethylsilyl (TBDMS) group.